The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trialAdriaan A. Voors, Piotr Ponikowski, Martina Brueckmann et al.|Nature Medicine|2022Cited by 889
Epidemiology, Pathophysiology and Contemporary Management of Cardiogenic Shock – A Position Statement from the Heart Failure Association of the European Society of CardiologyOvidiu Chioncel, Petar Seferović, John Parissis et al.|European Journal of Heart Failure|2020Cited by 489
Organ Dysfunction, Injury and Failure in Acute Heart Failure: From Pathophysiology to Diagnosis and Management. A Review on Behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)Veli‐Pekka Harjola, Alexandre Mebazaa, Wilfried Müllens et al.|European Journal of Heart Failure|2017Cited by 406
Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trialJan Biegus, Piotr Ponikowski, Adriaan A. Voors et al.|European Heart Journal|2022Cited by 213
The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea studyAlexandre Mebazaa, Mihai Gheorghiade, Peter S. Pang et al.|European Heart Journal|2009Cited by 188